Collate has secured $95 million in Series A funding to enhance its AI-native platform aimed at regulated workflows in the life sciences sector. Led by investors including Redpoint Ventures and Y Combinator, this capital will help the company deliver patient-first AI solutions tailored for the pharmaceutical and life sciences industries. Founded by CEO Surbhi Sarna, Collate’s software automates regulated processes with pre-built workflows that reduce the need for extensive customization. As demand for AI tools grows in regulated environments, Collate plans to expand its capabilities to support various critical functions in life sciences.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://pulse2.com/collate-raises-95-million-series-a-to-expand-ai-platform-for-regulated-life-sciences-workflows/
